QRG Capital Management Inc. Reduces Position in Boston Scientific Corporation $BSX

QRG Capital Management Inc. cut its stake in Boston Scientific Corporation (NYSE:BSX) by 10.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 163,973 shares of the medical equipment provider’s stock after selling 18,627 shares during the period. QRG Capital Management Inc.’s holdings in Boston Scientific were worth $16,009,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Boston Scientific during the second quarter worth approximately $2,089,937,000. Edgewood Management LLC purchased a new stake in Boston Scientific during the second quarter worth about $746,655,000. Parnassus Investments LLC grew its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after buying an additional 6,868,459 shares during the period. Bessemer Group Inc. lifted its position in shares of Boston Scientific by 14,391.8% during the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 93,095 shares of company stock valued at $9,305,450 over the last three months. 0.50% of the stock is owned by company insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Trading Down 2.1%

Shares of BSX opened at $88.13 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The stock has a fifty day moving average of $96.90 and a two-hundred day moving average of $100.32. The company has a market capitalization of $130.65 billion, a PE ratio of 47.13, a price-to-earnings-growth ratio of 1.59 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter last year, the firm posted $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BSX. Morgan Stanley lifted their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $123.89.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.